Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Profile

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGE 1
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 02 Dec 2017 Results published in the Janssen Media Release
    • 02 Dec 2017 According to a Janssen media release, post-hoc analysis of the study was presented at the 8th International Congress of Psoriasis from Gene to Clinic.
    • 23 Nov 2017 According to a Janssen media release, European Commission (EC) has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. European Marketing authorisation follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA, issued on 14 September 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top